I'm LongbridgeAI, I can summarize articles.J.P. Morgan Asset Management has appointed Bruce N. Rogers as a venture partner at its Life Sciences Private Capital division. Rogers currently serves as president and CEO of a precision immunology portfolio company. Previously, he led Morphic Therapeutic through its $3.2 billion acquisition by Eli Lilly, where he later served as senior vice president and CEO. His prior experience includes roles at Pfizer and Pharmacia in medicinal chemistry.
- J.P. Morgan Asset Management named Bruce N. Rogers as venture partner at Life Sciences Private Capital. * Rogers is president and CEO of a precision immunology portfolio company focused on selectively targeting disease-driving T-cell populations. * He previously led Morphic Therapeutic, joining as chief scientific officer in 2016 and later serving as president through its USD 3.2 billion sale to Lilly. * Rogers later became senior vice president and CEO of Morphic at Lilly, overseeing portfolio and team integration. * Earlier roles included head of Neuro-Opportunities at Pfizer, following 16 years in medicinal chemistry at Pfizer and Pharmacia. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JP Morgan Asset Management Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here